Beyond the basics: the differential effects of demographics and hepatitis status on treatment outcome in hepatocellular carcinoma
- PMID: 23838536
- DOI: 10.1159/000352005
Beyond the basics: the differential effects of demographics and hepatitis status on treatment outcome in hepatocellular carcinoma
Comment on
-
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.Oncology. 2013;85(1):44-52. doi: 10.1159/000350841. Epub 2013 Jul 4. Oncology. 2013. PMID: 23838576 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
